Business Wire

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple Sclerosis

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, today announced that the U.S. Food and Drug Administration (FDA) ...
Nasdaq

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

- Targeted enrollment of 168 RRMS patients achieved in December 2024 - The last patient is expected to complete the trial in the third quarter of 2025 SAN DIEGO--(BUSINESS WIRE)-- Contineum ...